Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × Cytarabine × Clear all

Phase

Phase 3 3 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 196 Leukemia 110 Lymphoma 90 Precursor Cell Lymphoblastic Leukemia-Lymphoma 86 Burkitt Lymphoma 52 Myelodysplastic Syndromes 47 Lymphoma, Mantle-Cell 47 Lymphoma, Large B-Cell, Diffuse 47 Lymphoma, Non-Hodgkin 46 Leukemia, Myelomonocytic, Acute 30 Lymphoma, Follicular 29 Leukemia, Monocytic, Acute 29 Recurrence 25 Congenital Abnormalities 25 Leukemia, Erythroblastic, Acute 24 Lymphoma, Large-Cell, Immunoblastic 23 Leukemia, Megakaryoblastic, Acute 23 Blast Crisis 21 Hodgkin Disease 20 Leukemia, Lymphocytic, Chronic, B-Cell 18 Leukemia, Myelomonocytic, Chronic 17 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17 Lymphoma, B-Cell, Marginal Zone 15 Anemia, Refractory, with Excess of Blasts 15 Leukemia, Myeloid, Accelerated Phase 13 Leukemia, Biphenotypic, Acute 13 Leukemia, Myeloid, Chronic-Phase 12 Dendritic Cell Sarcoma, Interdigitating 12 Myeloproliferative Disorders 11 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10

Interventions

Oxaliplatin 67 Capecitabine 60 Fluorouracil 58 Bevacizumab 54 Gemcitabine 51 Paclitaxel 50 Leucovorin 50 Irinotecan 40 Docetaxel 39 Carboplatin 39 Cisplatin 38 pembrolizumab 37 Nivolumab 36 Cetuximab 35 Sunitinib 25 Trastuzumab 24 Radiosurgery 24 Radiotherapy 21 Doxorubicin 21 Cyclophosphamide 21 Panitumumab 20 Drug Therapy 19 Pemetrexed 18 Everolimus 18 Sorafenib 17 Interleukin-2 16 Fulvestrant 16 Albumin-Bound Paclitaxel 16 atezolizumab 15 Erlotinib Hydrochloride 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02067143 2021-09-08

LAL1913

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed

Neoplasm Metastasis, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡